Galderma is expanding its regional presence with the launch of Alastin, its premium regenerative skincare brand, in Japan, Singapore, South Korea and Taiwan. The move adds to the company’s footprint in Asia Pacific as it pushes further into markets seen as important for dermatological skincare and medical aesthetics.
The latest rollout comes after Alastin’s more recent launches in China and Australia. Together, those steps signal a broader strategy by Galderma to deepen its investment in the Japan and Asia Pacific region, where consumer interest in advanced skincare and aesthetic treatments has been growing quickly.
According to the company’s announcement, the JPAC market stands out as one of the fastest-growing globally for medical aesthetics and dermatological skincare. That growth has been supported by sophisticated skincare routines, strong demand for innovation and a market environment that increasingly favors premium treatment and skincare offerings.
By bringing Alastin into additional key markets, Galderma is positioning the brand to benefit from rising regional demand while broadening its portfolio across Asia Pacific. The expansion highlights the company’s focus on markets where skincare science and aesthetics continue to gain momentum.
